- Market cap
- Revenue
- Net income
- Cash on hand
- Gross margin
- Net margin
- EPS
- P/E ratio
Data from Pivotal Clinical Trials to be Presented in Five Poster Presentations at the 2022 American College of Allergy, Asthma and Immunology Annual Scientific Meeting Data Support New Drug Application for neffy®, Currently Under Review with U.S. FDA SAN DIEGO – November 10, 2022 – ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) (ARS or the Company), a […]
Over $280 Million in Combined Cash and Securities and at least Three Years Operating Runway to Support Launch and Commercialization of neffy® in the U.S., if Approved NDA Currently Under FDA Review; PDUFA Anticipated Mid-2023 MAA validated in the European Union Under Review SAN DIEGO – November 8, 2022 – ARS Pharmaceuticals, Inc. (Nasdaq: SPRY) […]
neffy has potential to be the first non-injectable medicine indicated to treat allergic reactions (type I) including anaphylaxis in the U.S., if approved SAN DIEGO – October 21, 2022 – ARS Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for review ARS’ New Drug Application (NDA) for neffy for […]
Silverback Therapeutics and ARS Pharmaceuticals, Inc. Conference Call July 21, 2022 at 5:00 PM EDT Conference Call
Transaction to support potential commercialization of neffy™, ARS’s needle-free epinephrine nasal spray Well-funded with at least three years of operating runway expected Companies to host conference call today, July 21, 2022, at 5:00 p.m. ET SEATTLE and SAN DIEGO – July 21, 2022 – Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”) and ARS Pharmaceuticals, Inc. […]
Appointments Further Strengthen Leadership Team to Support Launch Preparations for neffy™ (epinephrine nasal spray) SAN DIEGO – April 05, 2022 – ARS Pharmaceuticals, Inc., a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced the expansion of its executive leadership team with […]
SAN DIEGO – February 09, 2022 – ARS Pharmaceuticals, Inc., a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced the expansion of its executive leadership team with the appointments of Harris Kaplan as executive vice president, commercial strategy […]
Data will highlight patient outcomes of pharmacokinetics, pharmacodynamics, and safety of neffy™ (ARS-1), with simple intranasal epinephrine administration and other epinephrine intramuscular injection devices SAN DIEGO – February 2, 2022 – ARS Pharmaceuticals, Inc., will share new data on neffy highlighting our innovative intranasal treatment of type 1 severe allergic reactions including anaphylaxis at the […]
San Diego, Calif. – August 31, 2021 – ARS Pharmaceuticals, Inc., a pharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions potentially leading to anaphylaxis, has closed on a Series D financing of $55 million led by SR One with participation from RA Capital Management, and one […]
SAN DIEGO – May 13, 2021 – ARS Pharmaceuticals, Inc., a pharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions potentially leading to anaphylaxis, today announced the appointment of biotech leader and visionary Brent Saunders to its Board of Directors. Mr. Saunders currently serves as chief executive […]
